| scholarly article | Q13442814 |
| P50 | author | Christian Hartinger | Q21964885 |
| Paul Dyson | Q50080139 | ||
| P2093 | author name string | Soumya Chatterjee | |
| Arindam Bhattacharyya | |||
| Subhadip Kundu | |||
| P2860 | cites work | Up-regulation of c-Jun-NH2-kinase pathway contributes to the induction of mitochondria-mediated apoptosis by alpha-tocopheryl succinate in human prostate cancer cells. | Q25255636 |
| The biochemistry of apoptosis | Q29547741 | ||
| The p53 pathway: positive and negative feedback loops | Q29617535 | ||
| Cellular effects of transferrin coordinated to. | Q32120726 | ||
| Development of organometallic ruthenium-arene anticancer drugs that resist hydrolysis | Q33260994 | ||
| Regulation of the G2/M transition by p53. | Q33943437 | ||
| Ruthenium-based compounds and tumour growth control (review). | Q33966078 | ||
| The binding properties of two antitumor ruthenium(III) complexes to apotransferrin | Q34349095 | ||
| Interaction of tetra-azaphenanthrene ruthenium complexes with DNA and oligonucleotides. A photophysical and photochemical investigation | Q34484978 | ||
| From bench to bedside--preclinical and early clinical development of the anticancer agent indazolium trans-[tetrachlorobis(1H-indazole)ruthenate(III)] (KP1019 or FFC14A). | Q34511975 | ||
| New roles for p21 and p27 cell-cycle inhibitors: a function for each cell compartment? | Q35057304 | ||
| JNK targets p53 ubiquitination and degradation in nonstressed cells | Q35208651 | ||
| Role of JNK activation in apoptosis: a double-edged sword | Q36027363 | ||
| Enabling death by the Abl tyrosine kinase: mechanisms for nuclear shuttling of c-Abl in response to DNA damage | Q36140014 | ||
| Metal-based antitumour drugs in the post genomic era. | Q36446191 | ||
| Mechanisms of cytochrome c release from mitochondria | Q36468900 | ||
| Interactions of antitumor metallodrugs with serum proteins: advances in characterization using modern analytical methodology. | Q36505391 | ||
| Antitumour metal compounds: more than theme and variations | Q37039611 | ||
| In vitro and in vivo activity and cross resistance profiles of novel ruthenium (II) organometallic arene complexes in human ovarian cancer | Q37352731 | ||
| TGFbeta influences Myc, Miz-1 and Smad to control the CDK inhibitor p15INK4b | Q39420254 | ||
| Ruthenium (II)-derived organometallic compounds induce cytostatic and cytotoxic effects on mammalian cancer cell lines through p53-dependent and p53-independent mechanisms. | Q40371896 | ||
| In vitro and in vivo evaluation of ruthenium(II)-arene PTA complexes | Q40412362 | ||
| Redox-active antineoplastic ruthenium complexes with indazole: correlation of in vitro potency and reduction potential | Q40435760 | ||
| Investigation of the role of Bax, p21/Waf1 and p53 as determinants of cellular responses in HCT116 colorectal cancer cells exposed to the novel cytotoxic ruthenium(II) organometallic agent, RM175. | Q40455509 | ||
| Survivin and p53 modulate quercetin-induced cell growth inhibition and apoptosis in human lung carcinoma cells | Q40509371 | ||
| Senescence-like changes induced by expression of p21(waf1/Cip1) in NIH3T3 cell line | Q40701845 | ||
| Long-patch base excision repair of apurinic/apyrimidinic site DNA is decreased in mouse embryonic fibroblast cell lines treated with plumbagin: involvement of cyclin-dependent kinase inhibitor p21Waf-1/Cip-1. | Q40709907 | ||
| Is there life after technetium: what is the potential for developing new broad-based radionuclides? | Q40944894 | ||
| Effects of hypoxia and transferrin on toxicity and DNA binding of ruthenium antitumor agents in hela cells | Q43203460 | ||
| Prodigiosin induces caspase-9 and caspase-8 activation and cytochrome C release in Jurkat T cells | Q44251672 | ||
| Regulation of Bax translocation through phosphorylation at Ser-70 of Bcl-2 by MAP kinase in NO-induced neuronal apoptosis. | Q44627821 | ||
| A comparative study of adduct formation between the anticancer ruthenium(III) compound HInd trans-[RuCl4(Ind)2] and serum proteins. | Q44900874 | ||
| A Phase I and pharmacological study with imidazolium-trans-DMSO-imidazole-tetrachlororuthenate, a novel ruthenium anticancer agent. | Q44918007 | ||
| Tuning the hydrophobicity of ruthenium(II)-arene (RAPTA) drugs to modify uptake, biomolecular interactions and efficacy | Q46907964 | ||
| Platinum group metallodrug-protein binding studies by capillary electrophoresis - inductively coupled plasma-mass spectrometry: a further insight into the reactivity of a novel antitumor ruthenium(III) complex toward human serum proteins | Q46914255 | ||
| Correlation of p53 and bcl-2 expression with vascular endothelial growth factor (VEGF), microvessel density (MVD) and clinico-pathological features in colon cancer. | Q47606734 | ||
| A new cholescintigraphic agent: ruthenium-97-DISIDA. | Q50157054 | ||
| Heterocyclic complexes of ruthenium(III) induce apoptosis in colorectal carcinoma cells. | Q53881839 | ||
| Redox behavior of tumor-inhibiting ruthenium(iii) complexes and effects of physiological reductants on their binding to GMP | Q60240481 | ||
| Antitumor activity of some ruthenium derivatives in human colon cancer cell lines in vitro | Q67916891 | ||
| Antineoplastic activity of three ruthenium derivatives against chemically induced colorectal carcinoma in rats | Q68074891 | ||
| Efficacy of new ruthenium complexes against chemically induced autochthonous colorectal carcinoma in rats | Q69690609 | ||
| Current status of platinum-based antitumor drugs | Q77367180 | ||
| A calmodulin-binding site on cyclin E mediates Ca2+-sensitive G1/s transitions in vascular smooth muscle cells | Q83181592 | ||
| P433 | issue | 7 | |
| P921 | main subject | ruthenium | Q1086 |
| P304 | page(s) | 1149-1155 | |
| P577 | publication date | 2008-07-03 | |
| P1433 | published in | Journal of Biological Inorganic Chemistry | Q3186899 |
| P1476 | title | The ruthenium(II)-arene compound RAPTA-C induces apoptosis in EAC cells through mitochondrial and p53-JNK pathways | |
| P478 | volume | 13 |
| Q39241586 | 3-Hydroxyflavones vs. 3-hydroxyquinolinones: structure-activity relationships and stability studies on Ru(II)(arene) anticancer complexes with biologically active ligands |
| Q39570737 | A bifunctional organometallic ruthenium drug with multiple modes of inducing apoptosis |
| Q37709331 | A ruthenium anticancer compound interacts with histones and impacts differently on epigenetic and death pathways compared to cisplatin. |
| Q52872859 | Alteration of steric hindrance modulates glutathione resistance and cytotoxicity of three structurally related Ru(II)-p-cymene complexes. |
| Q36396542 | Altered DNA binding and amplification of human breast cancer suppressor gene BRCA1 induced by a novel antitumor compound, [Ru(η(6)-p-phenylethacrynate)Cl(2)(pta)]. |
| Q85641063 | An insight into the anticancer activities of Ru(II)-based metallocompounds using docking methods |
| Q90334551 | Anticancer Ruthenium(III) Complexes and Ru(III)-Containing Nanoformulations: An Update on the Mechanism of Action and Biological Activity |
| Q39619138 | Antiproliferative activity of chelating N,O- and N,N-ruthenium(II) arene functionalised poly(propyleneimine) dendrimer scaffolds |
| Q50092474 | Antitumor effectiveness and mechanism of action of Ru(II)/amino acid/diphosphine complexes in the peritoneal carcinomatosis progression. |
| Q39706669 | Arene ruthenium complexes as anticancer agents |
| Q91843271 | Binding mechanisms of half-sandwich Rh(III) and Ru(II) arene complexes on human serum albumin: a comparative study |
| Q37325076 | Biomedical and biochemical applications of self-assembled metallacycles and metallacages |
| Q35089211 | Cellular responses of BRCA1-defective and triple-negative breast cancer cells and in vitro BRCA1 interactions induced by metallo-intercalator ruthenium(II) complexes containing chloro-substituted phenylazopyridine |
| Q41859133 | Chlorido(η(6)-N (2)-diphenylphosphanyl-N (1),N (1)-diisopropyl-4-methoxybenz-amidine-κP)(triphenylphosphane-κP)ruthenium(II) trifluoromethansulfonate acetone disolvate. |
| Q37657640 | Combination of ruthenium(II)-arene complex [Ru(η6-p-cymene)Cl2(pta)] (RAPTA-C) and the epidermal growth factor receptor inhibitor erlotinib results in efficient angiostatic and antitumor activity |
| Q86489694 | Comparing the suitability of autodock, gold and glide for the docking and predicting the possible targets of Ru(II)-based complexes as anticancer agents |
| Q115034988 | Competitive binding studies of the nucleosomal histone targeting drug, [Ru(η6-p-cymene)Cl2(pta)] (RAPTA-C), with oligonucleotide-peptide mixtures. |
| Q46014374 | Computational properties of η6-toluene and η6-trifluorotoluene half-sandwich Ru(II) anticancer complexes. |
| Q35664830 | Conjugation of organoruthenium(II) 3-(1H-benzimidazol-2-yl)pyrazolo[3,4-b]pyridines and indolo[3,2-d]benzazepines to recombinant human serum albumin: a strategy to enhance cytotoxicity in cancer cells |
| Q37603642 | Current applications and future potential for bioinorganic chemistry in the development of anticancer drugs. |
| Q47272198 | Cytotoxicity in vitro, cellular uptake, localization and apoptotic mechanism studies induced by ruthenium(II) complex. |
| Q108003603 | Drug Repurposing to Identify a Synergistic High-Order Drug Combination to Treat Sunitinib-Resistant Renal Cell Carcinoma |
| Q38963924 | Drug conjugation to cyclic peptide-polymer self-assembling nanotubes. |
| Q43756596 | Effects of bidentate coordination on the molecular properties rapta-C based complex using theoretical approach |
| Q64268057 | Elucidation of the Mechanism of Action for Metal Based Anticancer Drugs by Mass Spectrometry-Based Quantitative Proteomics |
| Q52713012 | Enhanced Antimetastatic Activity of the Ruthenium Anticancer Drug RAPTA-C Delivered in Fructose-Coated Micelles. |
| Q51767884 | Exploring metallodrug-protein interactions by mass spectrometry: comparisons between platinum coordination complexes and an organometallic ruthenium compound. |
| Q33869892 | FAB, ESI and MALDI Mass Spectrometric methods in the study of metallo-drugs and their biomolecular interactions |
| Q50001951 | Half-Sandwich Ru(II) and Os(II) Bathophenanthroline Complexes Containing a Releasable Dichloroacetato Ligand |
| Q53774494 | Heterodinuclear Pt(iv)-Ru(ii) anticancer prodrugs to combat both drug resistance and tumor metastasis. |
| Q60389740 | In vitro Cytotoxicity of Half-Sandwich Platinum Group Metal Complexes of a Cationic Alkylated Phosphaadamantane Ligand |
| Q33626165 | In-Cell Activation of Organo-Osmium(II) Anticancer Complexes |
| Q59011264 | Insights into the Intramolecular Properties ofη6-Arene-Ru-Based Anticancer Complexes Using Quantum Calculations |
| Q43729194 | Insights into the binding sites of organometallic ruthenium anticancer compounds on peptides using ultra-high resolution mass spectrometry |
| Q39788647 | Maltol-derived ruthenium-cymene complexes with tumor inhibiting properties: the impact of ligand-metal bond stability on anticancer activity in vitro |
| Q38199383 | Metallomics insights into the programmed cell death induced by metal-based anticancer compounds. |
| Q54209288 | Microwave-assisted synthesis of arene ruthenium(II) complexes [(η⁶-RC₆H₅)Ru(m-MOPIP)Cl]Cl (R = -H and -CH₃) as groove binder to c-myc G4 DNA. |
| Q36853421 | Mir-375 enhances ruthenium-derived compound Rawq01 induced cell death in human ovarian cancer |
| Q39052398 | Mitochondria are the primary target in the induction of apoptosis by chiral ruthenium(II) polypyridyl complexes in cancer cells |
| Q35029887 | New ruthenium(II) arene complexes of anthracenyl-appended diazacycloalkanes: effect of ligand intercalation and hydrophobicity on DNA and protein binding and cleavage and cytotoxicity |
| Q39031995 | Novel heterobimetallic radiotheranostic: preparation, activity, and biodistribution |
| Q39229950 | Organometallic anticancer agents that interfere with cellular energy processes: a subtle approach to inducing cancer cell death |
| Q62459397 | Photodissociation of a ruthenium(II) arene complex and its subsequent interactions with biomolecules: a density functional theory study |
| Q42725980 | Physicochemical Studies and Anticancer Potency of Ruthenium η-p-Cymene Complexes Containing Antibacterial Quinolones |
| Q110424723 | Recent Considerations in the Application of RAPTA‐C for Cancer Treatment and Perspectives for Its Combination with Immunotherapies |
| Q38770155 | Regulating the anticancer properties of organometallic dendrimers using pyridylferrocene entities: synthesis, cytotoxicity and DNA binding studies |
| Q92321776 | Ru(II)-thymine complex causes DNA damage and apoptotic cell death in human colon carcinoma HCT116 cells mediated by JNK/p38/ERK1/2 via a p53-independent signaling |
| Q30403317 | Ruthenium anticancer compounds: myths and realities of the emerging metal-based drugs. |
| Q39121561 | Ruthenium-Arene-β-Carboline Complexes as Potent Inhibitors of Cyclin-Dependent Kinase 1: Synthesis, Characterization and Anticancer Mechanism Studies. |
| Q34102818 | Ruthenium-based chemotherapeutics: are they ready for prime time? |
| Q49687144 | Structure-activity relationships for ruthenium and osmium anticancer agents - towards clinical development |
| Q39178846 | Synthesis and characterization of a new class of anti-angiogenic agents based on ruthenium clusters |
| Q39497573 | Synthesis, structures, cellular uptake and apoptosis-inducing properties of highly cytotoxic ruthenium-Norharman complexes. |
| Q47196925 | Target profiling of an antimetastatic RAPTA agent by chemical proteomics: relevance to the mode of action |
| Q47159745 | Target profiling of an antimetastatic RAPTA agent by chemical proteomics: relevance to the mode of action† †Electronic supplementary information (ESI) available: Experimental, crystallographic, biological and mass spectrometric data, full list of pr |
| Q59062348 | The Spectroscopic and Conductive Properties of Ru(II) Complexes with Potential Anticancer Properties |
| Q39182036 | The induction of mitochondria-mediated apoptosis in cancer cells by ruthenium(II) asymmetric complexes |
| Q39246566 | The influence of RAPTA moieties on the antiproliferative activity of peripheral-functionalised poly(salicylaldiminato) metallodendrimers |
| Q33640724 | Transferring the concept of multinuclearity to ruthenium complexes for improvement of anticancer activity |
Search more.